Top Back to top

Use of eculizumab to treat thrombotic microangiopathy associated with haematopoietic stem cell transplantation - a retrospective study on behalf of the Paediatric Diseases and Inborn Errors Working Parties of the European Society of Blood and Marrow Transplantation

Paediatric Diseases Working Party (PDWP)
Study number:
 
Type of transplant:
 
Diseases:
 
Short title:
 
Study status:
 
Deadline for data collection:
 
Study design:
 
Primary objective:
Primary objective is to determine the effectivity of eculizumab treatment in HSCT-TMA in children.The goal is to collect the unpublished real-life experience of eculizumab use that may help the current practice and shape the future research.
Key inclusion criteria:
- Age 0-18yrs
- Allogeneic haematopoietic stem cell transplantation recipient
- HSCT-TMA diagnosed according to any of the 6 criteria listed (defined in the questionnaire, attached))
- Treatment with eculizumab
- Informed consent given for EBMT registry data collection
Country:
 
Principal investigator:
Peter Svec
Principal investigator email:
 
EBMT Study coordinator:
Arnaud Dalissier

Need help?

The personal data provided will be processed according to the General Data Protection Regulation (GDPR 2016/679 ) and incorporated to a file property of EBMT which will be allocated in the EEA (European Economic Area) or in countries that are provided with the same level of protection for privacy such as countries that adhere to EU-US and Swiss-US Privacy Shield Frameworks.
Data Subjects have the right of access to his or her data and the right to rectification of any inaccurate or incomplete personal data. The Data Subject also has the right to withdraw consent, this wish will be respected, and the personal will no longer be made available. If the processing operation is unlawful the Data Subject has the right to request deletion of that data. Please write to data.protection@ebmt.org